Amgen Non-GAAP EPS of $4.36 beats by $0.35, revenue of $6.85B misses by $20M
Amgen press release
(NASDAQ:AMGN): Q4 Non-GAAP EPS of $4.36  beats by $0.35.
Revenue of $6.85B (+3.3% Y/Y)  misses by $20M.
Revenue from the Eli Lilly and Company (Lilly) COVID-19 manufacturing collaboration. Product sales decreased 1% globally for the fourth quarter.
Additionally, the Company will provide financial guidance for 2022 and longer-term financial guidance through the end of the decade.